 |
| Associate Professor Jake Shortt |
Monash Health in affiliation with Monash University has been
approved as a "Myelodysplasia (MDS) Center of Excellence" by the
International MDS Foundation.
Associate Professor Jake Shortt said the application was
supported by publications from the Grigoriadis/Banerjee lab and from several
papers by Dr Zoe McQuilten and Associate Professor Erica Wood using data
linkage to ascertain patterns of MDS in Australia.
“We are also a frequent lead Australian site in recruitment
to MDS clinical trials, several of which are currently recruiting at the MHTP,”
said Associate Professor Shortt, Head of Haematology Research and clinical lead
for MDS and Leukaemia at the Monash Health Translation Precinct.
The
Myelodysplastic Syndromes Foundation was established by an international group
of physicians and researchers to provide an ongoing exchange of information
relating to MDS.
To be recognized as an MDS Center of Excellence, an institution
must have:
- An
established university (or equivalent) program
- Recognized
morphologic expertise in MDS
- Available
cytogenetics and/or molecular genetics
- Ongoing
research, including Institutional Review Board-approved clinical trials
- Documentation
of peer-reviewed publications in the field
Associate Professor Shortt said he looks forward to
progressing the acute leukaemia strategy as the next goal in the MDS and
Leukaemia program at MHTP.
No comments:
Post a Comment